Stretch marks and loss of skin elasticity send many people searching for topical ingredients with real backing. Palmitoyl tetrapeptide-7 shows up in one cosmetic label as an ingredient meant to support skin appearance rather than treat a medical condition.
Key takeaways
- Palmitoyl tetrapeptide-7 is labeled as an ingredient in a product called Stretch Marks cream.
- Its labeled use is cosmetic: reducing the look of scars and stretch marks and supporting skin elasticity.
- The product label classifies it under a non-standardized food allergenic extract category.
- One registered clinical trial has evaluated related skin treatments, and it has been completed.
- No boxed warning appears on the label, and no adverse event reports are on file in the data reviewed.
What Palmitoyl Tetrapeptide-7 Is
Palmitoyl tetrapeptide-7 is a small peptide compound (molecular formula C34H62N8O7) formulated into topical skin care products. It is identified in chemical databases under PubChem CID 10078408. The label does not describe a specific biological mechanism, so no mechanism of action can be reported here.
What Palmitoyl Tetrapeptide-7 Is Approved For
The labeled product, Stretch Marks cream, is described as helping to remove scars, repair skin, and enhance skin elasticity. Directions call for whole-body application with focus on the abdomen, used each morning and evening. This is a cosmetic labeling rather than a therapeutic drug indication, and no boxed warning is present.
What the Evidence Shows
One clinical trial appears in the available registry data involving skin treatments relevant to this category. That trial, a completed Phase 4 study, assessed facial skin quality, hydration, and skin barrier function across three Hydrafacial treatments in adults of various skin types. This trial does not evaluate palmitoyl tetrapeptide-7 directly, so it offers only indirect context for skin-focused research in this space.
Reported Side Effects
No adverse event reports for palmitoyl tetrapeptide-7 were found in the data reviewed. This absence reflects the available reporting data rather than confirmation of safety, since FAERS-style reports reflect submitted cases, not confirmed incidence or causation.